BriaCell Therapeutics Corp.
Save
55.62M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.

Similar securities

Based on sector and market capitalization

Report issue